Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 22, 2011

View Archived Issues

Novel CFTR channel inhibitors patented by Summit Corporation

Biogen Idec describes novel gamma-secretase modulator

Serum biomarker of muscle pathology in mitochondrial disorders identified

New B-raf inhibitors disclosed by IRM and Novartis

Japanese scientists present novel series of ASK-1 inhibitors

Novel anticancer compounds presented by Otsuka

Dana-Farber researchers claim novel B-raf inhibitors

Prana Biotechnology receives grant for novel Parkinson's disease therapy

EMA accepts for review submissions by Pfizer for two investigational anticancer therapies

Antimalarial Pyramax obtains approval in Korea

FDA grants accelerated approval to Adcetris for two indications

ALL-00179 allows transdermal delivery of cannabidiol with microneedles

GSK receives grant to advance dermal treatment based on Starpharma's dendrimers

FDA accepts for review resubmitted Adasuve NDA

Live-attenuated Chikungunya vaccine is immunogenic and efficacious in preclinical studies

Nycomed receives rights to MoviPrep in Russia and Commonwealth of Independent States

Pinnacle Pharmaceuticals studies PP-4001 for symptoms associated with UTI

Phase II trial of Diabecell begins in Argentina in patients with type 1 diabetes

Mochida signs agreement with Ajinomoto to take over Japanese distribution of Fastic

Lexapro launched in Japan

Santarus and Depomed enter new U.S. commercialization agreement for Glumetza

Health Canada approves Lucentis for vision loss due to retinal vein occlusion

Daiichi Sankyo files for additional indication for Diagnogreen

Evotec receives milestone payment for advancement of oncology compound

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...